Drugs that inhibit APOBEC enzymes will address unmet needs in mitigating cancer risk and cancer progression that are characteristic of B cell lymphoma and leukemia, breast cancer, colorectal cancer, head and neck cancer, hepatocellular carcinoma, stomach cancer, metastatic disease, non-small cell lung cancer and ovarian cancer.

Disease progress in a variety of cancers is widely recognized as driven by unregulated and off-target mutagenic activity by APOBEC enzymes on chromosomal DNA and yet this fundamental cancer mechanism remains an unmet need in drug discovery.

OyaGen’s unique high throughput assay for inhibitors of AID gene editing activity has been third part validated in identifying compounds that are selective inhibitors of the pathway AID uses to enter the cell nucleus and access chromosomal DNA.

Other high throughput assays that seek inhibitors APOBEC3A and APOBEC3B gene mutation activity are in concept and development stages. OyaGen has a platform of cell and molecular methods that will enable and validate hits from its oncology drug discovery campaign and accelerate hit-to-lead optimization and IND-enabling studies.